The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Increasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureus
Open accessAbstract
Strains of Staphylococcus aureus with reduced susceptibility to glycopeptides have been reported from Japan, the United States, Europe, and the Far East. Although isolates with homogeneous resistance to vancomycin (MICs = 8 microg/mL) continue to be rare, there are increasing reports of strains showing heteroresistance, often with vancomycin MICs in the 1-4 microg/mL range. Most isolates with reduced susceptibility to vancomycin appear to have developed from preexisting methicillin-resistant S. aureus infections. Many of the isolates with reduced susceptibility to glycopeptides have been associated with therapeutic failures with vancomycin. Although nosocomial spread of the vancomycin-intermediate S. aureus (VISA) strains has not been observed in U.S. hospitals, spread of VISA strains has apparently occurred in Japan. Broth microdilution tests held a full 24 hours are optimal for detecting resistance in the laboratory; however, methods for detecting heteroresistant strains are still in flux. Disk-diffusion tests, including the Stokes method, do not detect VISA strains. The Centers for Disease Control and Prevention and other groups have issued recommendations regarding appropriate infection control procedures for patients infected with these strains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
Staphylococcus aureus Infections
Lowy, F. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390806 · Cited by 6,005
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984
Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, Y., & Kobayashi, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07324-8 · Cited by 1,333
Weinstein, M. P., Towns, M. L., Quartey, S. M., Mirrett, S., Reimer, L. G., Parmigiani, G., & Barth Reller, L. (1997) · Clinical Infectious Diseases · doi:10.1093/clind/24.4.584 · Cited by 1,228
Emergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088
Self-citation(1995) · American Journal of Infection Control · doi:10.1016/0196-6553(95)90104-3 · Cited by 709
Sieradzki, K., Roberts, R. B., Haber, S. W., & Tomasz, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400704 · Cited by 638
The staphylococci in human disease
Crossley, K., & Archer, G. L. (1996) · Churchill Livingstone eBooks · Cited by 632
Tenover, F. C., Lancaster, M. V., Hill, B. C., Steward, C. D., Stocker, S. A., Hancock, G. A., O’Hara, C. M., Clark, N. C., & Hiramatsu, K. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.4.1020-1027.1998 · Cited by 376
Self-citationHanaki, H. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.2.199 · Cited by 366
Tenover, F. C., Lancaster, M. V., Hill, B. C., Steward, C. D., Stocker, S. A., Hancock, G. A., O’Hara, C. M., McAllister, S. K., Clark, N. C., & Hiramatsu, K. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.7.2167-2167.1998 · Cited by 362
Self-citationFirst clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
Ploy, M., Grelaud, C., Martin, C., de Lumley, L., & Denis, F. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79166-2 · Cited by 331
Historical Yearly Usage of Vancomycin
Kirst, H. A., Thompson, D. G., & Nicas, T. I. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1303 · Cited by 276
Vancomycin-resistant Staphylococcus aureus
Howe, R. A., Bowker, K. E., Walsh, T. R., Feest, T. G., & MacGowan, A. P. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78597-4 · Cited by 274
Valles, J., Leon, C., & Spanish Collaborative Group for Infections in Intensive Care Units of Sociedad Espanola de Medicina Intensiva y Unidades Coronarias (SEMIUC) (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.3.387 · Cited by 242
Staphylococcus aureus With Reduced Susceptibility to Vancomycin—United States, 1997
(1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550110029014 · Cited by 223
The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study
Ena, J. (1993) · JAMA · doi:10.1001/jama.269.5.598 · Cited by 203
Climo, M. W., Patron, R. L., & Archer, G. L. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1747 · Cited by 189
Geisel, R. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.6.846 · Cited by 181
Ariza, J., Pujol, M., Cabo, J., Peña, C., Fernández, N., Liñares, J., Ayats, J., & Gudiol, F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01017-x · Cited by 167
Rotun, S. S., McMath, V., Schoonmaker, D. J., Maupin, P. S., Tenover, F. C., Hill, B. C., & Ackman, D. M. (1999) · Emerging Infectious Diseases · doi:10.3201/eid0501.990118 · Cited by 167
Self-citationANTIMICROBIAL RESISTANCE IN STAPHYLOCOCCI
Maranan, M. C., Moreira, B., Boyle-Vavra, S., & Daum, R. S. (1997) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70392-5 · Cited by 166
Bacteremia Caused by Staphylococci with Inducible Vancomycin Heteroresistance
Wong, S. S. Y., Ho, P. L., Woo, P. C. Y., & Yuen, K. Y. (1999) · Clinical Infectious Diseases · doi:10.1086/520429 · Cited by 165
Hanaki, H., Labischinski, H., Inaba, Y., Kondo, N., Murakami, H., & Hiramatsu, K. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.3.315 · Cited by 155
Cockerill, F. R., Hughes, J. G., Vetter, E. A., Mueller, R. A., Weaver, A. L., Ilstrup, D. M., Rosenblatt, J. E., & Wilson, W. R. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.3.403 · Cited by 137
New Resistance inStaphylococcus aureus
Waldvogel, F. A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400709 · Cited by 130
Vancomycin-Resistant Staphylococcus aureus: Perspectives on Measures Needed for Control
Edmond, M. B., Wenzel, R. P., & Pasculle, A. W. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-3-199602010-00008 · Cited by 127
Reversion of the Glycopeptide Resistance Phenotype in Staphylococcus aureus Clinical Isolates
Boyle‐Vavra, S., Berke, S. K., Lee, J. C., & Daum, R. S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.272-277.2000 · Cited by 121
Pfeltz, R. F., Singh, V. K., Schmidt, J. L., Batten, M. A., Baranyk, C. S., Nadakavukaren, M. J., Jayaswal, R. K., & Wilkinson, B. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.294-303.2000 · Cited by 118
Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999.
Khurshid, M., Chou, T. D., Carey, R. A., Larsen, R. A., Conover, C. S., & Bornstein, S. (2000) · MMWR Morbidity and Mortality Weekly Report · Cited by 109
Presence of Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Germany
Bierbaum, G., Fuchs, K., Lenz, W., Szekat, C., & Sahl, H. (1999) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050380 · Cited by 106
1996 Report of the Comité de l'Antibiogramme de la Société Française de Microbiologie
Williams, J. D. (1997) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.1997.tb00639.x · Cited by 82
Hubert, S. K., Mohammed, J. M., Fridkin, S. K., Gaynes, R. P., McGowan, J. E., & Tenover, F. C. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.11.3590-3593.1999 · Cited by 79
Self-citationSieradzki, K., Roberts, R. B., Serur, D. S., Hargrave, J., & Tomasz, A. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.1.39-44.1999 · Cited by 78
Zimakoff, J., Pedersen, F. B., Bergen, L., Baagø-Nielsen, J., Daldorph, B., Espersen, F., Hansen, B. G., Høiby, N., Jepsen, O. B., Joffe, P., et al. (1996) · Journal of Hospital Infection · doi:10.1016/s0195-6701(96)90015-8 · Cited by 74
Cunha, B. A. (1995) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30041-4 · Cited by 73
Καντζάνου, Μ. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.5.729 · Cited by 51
Franchi, D., Climo, M. W., Wong, A. H. M., Edmond, M. B., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/313530 · Cited by 51
Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999.
(2000) · PubMed · Cited by 50
Johnson, A. P. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.3.289 · Cited by 33
Cited by
Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology
Lakhundi, S., & Zhang, K. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00020-18 · Cited by 1,637
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Levine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Arbeit, R. D., Maki, D., Tally, F. P., Campanaro, E., Eisenstein, B. I., & Daptomycin 98-01 and 99-01 Investigators (2004) · Clinical Infectious Diseases · doi:10.1086/420818 · Cited by 689
Coia, J. E., Duckworth, G. J., Edwards, D. I., Farrington, M., Fry, C., Humphreys, H., Mallaghan, C., & Tucker, D. R. (2006) · Journal of Hospital Infection · doi:10.1016/j.jhin.2006.01.001 · Cited by 544
Metadata
- Authors
- Tenover, F. C., Biddle, J. W., & Lancaster, M. V.
- Venue
- Emerging Infectious Diseases
- Published
- 2001-03
- Volume
- 7
- Issue
- 2
- Pages
- 327-332
- ISSN
- 1080-6040 (ISSN-L)
- 1080-6059
- OpenAlex
- W2027422681
- Cited by
- 391
- References
- 44
- FWCI
- 24.28
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.